Kornimate/medical-research-clean huggingface dataset:
observational study of acalabrutinib in patients with chronic lymphocytic leukaemia in the united kingdom

Conditions: Chronic Lymphocytic Leukemia, CLL

Summary: this is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with chronic lymphocytic leukaemia receiving acalabrutinib in the united kingdom (the epic study). physicians treating chronic lymphocytic leukaemia patients with acalabrutinib, where the patients started treatment as part of the acalabrutinib early access programme (eap), will be invited to recruit patients. clinical data will be extracted from the patients' clinical records in line with local laws. data from this study will provide uk-specific real-world data on patients who were started on acalabrutinib as part of the uk acalabrutinib eap.

1. primary objectives: a. to estimate real-world progression-free survival in patients with cll who received acalabrutinib in the first-line. 2. secondary objectives: 1. to estimate real-world overall survival in patients with cll who received acalabrutinib in the first-line. 2. to describe real-world response rate to acalabrutinib in patients with cll who received acalabrutinib in the first-line. 3. to describe the healthcare resource utilisation in patients with cll who received acalabrutinib in the first-line. 4. to describe post-progression treatment patterns in patients with cll who progressed from first-line acalabrutinib. 5. to describe real-world clinical progression free survival in patients with cll who received acalabrutinib in the first-line and progressed during acalabrutinib treatment. 6. to describe acalabrutinib treatment patterns in patients with cll who received acalabrutinib in the first-line. 7. to describe baseline clinical and demographic characteristics in patients with cll who received acalabrutinib in the first-line.

Eligibility criteria:
the study population will include treatment-naïve patients with chronic lymphocytic lymphoma (cll)\* who meet the following inclusion criteria: * treatment-naïve cll patients who were initiated on acalabrutinib as part of the uk early access programme * received their first dose of acalabrutinib between 1 april 2020 and 1 april 2021 * patients aged ≥18 years old * note: patients later found to have small lymphocytic lymphoma (sll) may also be included in the eap. exclusion criteria: - none listed in study protocol

Keywords: cll, real-world evidence, acalabrutinib
radial extracorporeal shock wave treatment (reswt) of myofascial pain syndrome in low back pain

Conditions: Myofascial Pain Syndromes; Low Back Pain; Lumbago

Summary: the purpose of this study is to evaluate the efficacy of treatment of radial shockwave in myofascial pain syndrome in the lumbar region compared to placebo through questionnaires and imaging exams.

background: extracorporeal shockwave treatment has been used widely for musculoskeletal conditions, however no randomized controlled trial are available about its use for chronic low back pain with myofascial pain syndrome (mps). hypothesis: radial extracorporeal shockwave treatment (reswt) improves pain intensity and functional disability compared with placebo in patients with chronic low back pain due to mps. study design: randomized controlled clinical trial methods: a prospective, randomized, double-blind, placebo-controlled study will be carried out on 40 patients who has moderate to severe pain (vas \> 4) for more than 6 months, despite 6 weeks of conservative treatment with antidepressants associated with rehabilitation. six interventions of reswt (3-4 bar; 1000 impulses per trigger point (tp) or 2500 impulses per muscle) will be compared with placebo. the outcome measures were pain visual analogue scale (vas), oswestry disability index, short-form mcgill pain questionnaire, roland morris disability questionnaire and the temperature of the treated area will be evaluated with thermography. the assessments will be apply before treatment, after conservative treatment, 6 and 12 weeks after reswt.

Eligibility criteria:
inclusion criteria: * presenting clinical complaints of lumbar and / or gluteal pains for 3 months or more * display pain of moderate to severe intensity: visual analogue scale (vas)\> 4 * diagnosis of myofascial pain syndrome in the lumbar and / or gluteal * authorize in writing the term of free and informed consent to participate in the study * availability of frequent attendance at hospital exclusion criteria: * organic or psychological disorders that contraindication participation of patients in study * metabolic, infectious, oncological or rheumatologic disorders * fibromyalgia * labor dispute * indication for surgery in column * contraindications to therapy of shock waves: * coagulopathy and / or anticoagulant * pregnancy * acute infection in soft tissue or bone * systemic infections * presence of ulcers at treatment sites * presence of larger vessels or nerves at treatment sites * polyneuropathies * malignancies * cardiac arrhythmias or use of pacemaker * epilepsy

Keywords: myofascial pain syndromes myofascial trigger point low back pain lumbago shock waves, high-energy high-energy shock waves interdisciplinary health team multidisciplinary pain centers
fotonovela for type 2 diabetes mellitus

Conditions: Type 2 Diabetes

Summary: diabetes with poor sugar control can lead to blindness, heart attacks, and amputations. latinos are more at risk for diabetes. a fotonovela is a type of comic book commonly read by latinos that might be a way to teach them about the risk of high sugars. the researchers will give patients either a fotonovela about diabetes or one with nothing to do with diabetes. then they will compare how well sugars were controlled afterward in each group. this way they can see if these fotonovelas were useful.

elevated glucose in diabetics is a risk for amputation, renal failure, coronary artery disease, neuropathy, and blindness. controlling glucose better as measured by hemoglobin a1c (a1c) reduces risk for these complications. information itself is often not enough to change behaviors that increase risk for these complications. latinos in america are particularly at risk for diabetes (dm) and its complications. a fotonovela is a booklet telling a story using photos with superimposed speech bubbles much like an american style comic book. these are commonly read by latinos. a fotonovela that tells a story about diabetes complications in a culturally appropriate context that emphasized impact on family might help motivate hispanic patients to control their sugar better. we propose a single-blinded, randomized, controlled trial of a dm themed fotonovela against a non-dm themed fotonovela to assess its effect on glycemia as measured by a1c. after a primary care provider has seen a latino type 2 diabetic patient, the investigator will consent them then give them an envelope with the dm themed fotonovela or another that is indistinguishable in the sealed envelope. the primary outcome is hemoglobin a1c one month or more after randomization. secondary outcomes will a1c in the 1-5 month and 6-12 month time period looking for durability of effect. a sample size of 260 allows for a 30% fallout and gives an 80% power to detect a 0.5% change in a1c with a 1.2% standard deviation on that change with a two-tailed alpha of 0.05.

Eligibility criteria:
inclusion criteria: * a1c\> 7.0 exclusion criteria: * pregnant

Keywords: diabetes fotonovela latino
the effect of acupuncture on ivf pregnancy outcomes for women with rif

Conditions: Repeated Implantation Failure

Summary: the randomized, placebo-controlled multicenter trial is conducted in five centers in china. after screening and obtaining the signed informed consent , the participants are randomly divided into two groups: acupuncture +ivf group and sham acupuncture +ivf group.


Eligibility criteria:
inclusion criteria: 1. married women aged 25-40; 2. repeated implantation failure for unknown reasons (after 3 or more consecutive cycles of embryo transfer, or cumulative transfer of ≥6 high-quality cleavage embryos or 4 high-quality blastocysts without clinical pregnancy); 3. transplantable day 3 high-quality frozen embryos or frozen blastocysts (≥3bb); 4. estrogen and progesterone replacement therapy (hrt), endometrial thickness ≥7mm on the day of endometrial transformation. exclusion criteria: patients who met any of the following conditions were not included. 1. those who prepare for pgd; 2. recipients of egg donors; 3. chromosomal abnormalities in both or one of the couples (excluding chromosome polymorphism); 4. patients with implantation failure due to known embryonic factors; 5. uterine lesions that may affect implantation (including uterine malformation, uterine tuberculosis, history of intrauterine adhesions, submucosal fibroids, adenomyosis, \>4cm intramural fibroids) 6. repeated spontaneous abortion (2 or more fetal loss before 28 weeks of gestation); 7. patients with other endocrine diseases, such as thyroid disease, hyperprolactinemia, insulin resistance, diabetes, adrenal disease, etc., and poor control of hormone levels in the last 3 months; 8. clearly diagnosed autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid syndrome, etc.; 9. hydrosalpinx untreated; 10. bmi less than 18 and higher than 25kg/m2; 11. people with previous history of needle sickness; 12. those who had previously participated in this study or had received acupuncture treatment in the past 3 months. 13. any situation that researchers consider inappropriate for participating in this study.
comparison of subgingival mechanotherapy with and without the use of a perioscope: clinical trial

Conditions: Periodontitis

Summary: the study aims to comparatively assess clinical parameters, biochemical and microbiological parameters after treatment of periodontitis using subgingival mechanotherapy traditional and subgingival mechanotherapy using a perioscope.

non-surgical treatment is the basic form of disease treatment periodontitis. its first stage is the mechanical removal of dental plaque along with the control of risk factors. subgingival mechanotherapy, also known as scaling and root planing (srp) is the next stage, aimed at the subgingival area. perioscopy makes possible direct real-time visualization of the root surface during the procedure. the research results published so far indicate improvement or no significant differences clinical parameters after srp procedure using a perioscope vs traditional subgingival instrumentation. the aim of this study is to indicate, or not, clinical, biochemical (level of pro-inflammatory cytokines) and microbiological (a. actinomycetemcomitans, p. gingivalis, t. denticola) differences after periodontitis treatment using the traditional method vs. using a perioscope.

Eligibility criteria:
inclusion criteria: * age 20-60; (ii) * preserved lateral and anterior teeth; * no periodontal treatment in the last 12 months; * intermediate or advanced periodontitis (stage ii / iii / iv) * in each quadrant at least three teeth with ppd\>5 mm after initial treatment (scaling, motivation, instruction) exclusion criteria: * antibiotic therapy in the last 6 months; * smoking; * systemic diseases affecting periodontal tissues; * pregnancy or lactation; * orthodontic treatment; * tooth mobility ii / iii degree; * involvement of third degree furcations according to hamp classification; * endodontic issues

Keywords: periodontal endoscopy, perioscopy
epidural fentanyl-bupivacaine versus clonidine-bupivacaine for breakthrough pain in advanced labor

Conditions: Labor Pain

Summary: epidural analgesia is widely regarding as the most effective analgesic strategy for labor pain. modern practice is to utilize dilute local anesthetics as a continuous infusion along with an opioid, e.g., our common "recipe" of 12 ml/hr of 0.0625% bupivacaine with 2 micrograms/ml fentanyl, after the initial dose to maintain patient comfort until delivery. this dose of the infusion often provides adequate comfort without interfering with the mobility of the patient and her ability to effectively push during delivery. however, this low dose epidural infusion strategy often results in recurrence of pain after an initial pain free period. this breakthrough pain is treated by administering small boluses of analgesics via the epidural catheter. the pain occurring in labor is initially of visceral origin and is mediated by pain fibers originating from the low thoracic and upper lumbar segments of the spinal cord. as labor progresses to the late first phase (also known as transitional stage), pain sensations originating from the distension of the pelvic floor, vagina and perineum adds a somatic component to labor pain. this type of breakthrough pain is often difficult to treat. although requests from patients to alleviate late stage breakthrough pain are common, no one knows the most effective strategy for pain management in this stage of labor. this study is designed to compare the efficacy of two treatments for controlling late first stage breakthrough pain during labor with an epidural infusion in place: clonidine-bupivacaine versus fentanyl-bupivacaine. women who have labor epidural analgesia in place will be enrolled to be randomized if and when they present with breakthrough pain in the late first stage or second stage of labor (≥ 8 cm dilated). they will receive 8 ml of a solution containing 10 mg bupivacaine and 75 micrograms of either fentanyl (an opioid or "narcotic") or clonidine (an "alpha-2 agonist known to be effective as an epidural analgesic). pain relief, labor progress and outcome will be assessed to compare fentanyl versus clonidine. it is the hypothesis of this study that clonidine added to bupivacaine is a better analgesic than fentanyl added to bupivacaine for breakthrough pain in advanced labor.


Eligibility criteria:
inclusion criteria: * women in labor at term pregnancy * healthy * epidural analgesia in place * breakthrough pain in advanced labor exclusion criteria: * chronic pain syndrome * receiving systemic opioids within 4 hours * receiving chronic antidepressants, clonidine, opioids

Keywords: analgesia epidural pregnancy labor clonidine fentanyl bupivacaine childbirth
study of rubella immunity. response to vaccination of subjects with very low, equivocal or undetectable titers of rubella virus antibodies

Conditions: Pregnancy

Summary: the aim of the research is to study humoral and cellular immunity in pregnant women for who the level of rubella virus antibodies is weakly positive, equivocal or negative with the usual laboratory technique.


Eligibility criteria:
inclusion criteria: * women over 18 * rubella serology negative, ambiguous or weakly positive during a first prenatal consultation and for which the second determination of the immunity anti rubella is necessary after 18 weeks of pregnancy * accepting the rubella vaccination after the childbirth; * accepting a blood test, during a postnatal consultation, 6 in 8 weeks after vaccination, to verify their immunity towards the virus of the rubella. * affiliated to a social security scheme * having given a written consent exclusion criteria: * rubella contracted since the first serology realized during the first prenatal consultation * autoimmune pathologies * intolerance / allergy known about a previous vaccination whatever it is * immunosuppression (hiv, transplants) * injection of multivalent immunoglobulins (except anti-d)

Keywords: rubeola
postoperative oral cryotherapy in sore throat and daily life

Conditions: Sleep Apnea, Obstructive

Summary: the purpose of this study will to evaluate the degree of postoperative sore throat and life impairment changes in patients with sleep apnea who underwent da vinci robotic arm surgery as an intervention of oral cryotherapy.

an experimental study was conducted with 32 patients in the experimental group and 32 patients in the control group. the experimental group used drinking water from a water dispenser with regular filter replacement and maintenance, plus a 2x5x7 cm (50 ml) ice lolly module to make ice lollies,and then intervened in the postsurgical period using oral cold therapy (ice lolly in the mouth),while the control group received general routine care. the control group received regular care. the assessment tools included the pain profile scale and the life impairment scale, and the assessment period was from the first day to the 14th day after the operation.

Eligibility criteria:
inclusion criteria: * (1)admission age is 18 years or above, conscious, able to communicate in mandarin and taiwanese, and willing to be measured and fill out the questionnaire after explaining the process and purpose of the study. * (2) the study was conducted in hospitalised patients diagnosed with sleep apnea who underwent surgery. exclusion criteria: * (1) diagnostic diagnosis of the disease not clearly known. * (2) patients with unclear consciousness. * (3) patients who have been diagnosed with mental illness before the diagnosis of the - * disease or recently diagnosed with mental illness. * (4) people with paraplegia or low behavioural ability. * (5) patients who have suffered a stroke.

Keywords: obstructive sleep apnea syndrome oral cryotherapy pain daily life
cannabinoid receptor (cb1) agonist treatment in severe chronic anorexia nervosa

Conditions: Anorexia Nervosa

Summary: a pilot study designed to reveal the effects of marinol / dronabinol, a cb 1 agonist. primary end point: to estimate weight gain and edi scores in patients receiving marinol compared to placebo secondary end points: motor and inner restlessness and hormonal changes during the treatment.

the goals of this study are to reveal through a pilot trial if treatment of patients with severe chronic an with marinol® (dronabinol, a cb1 agonist) has significant effect on: * weight * eating disorder inventory (edi) scale * motor and inner restlessness (estimated by accelerometry) * endocrine parameters (see below, paragraph 4.4) this study is a randomized, double blinded, placebo controlled cross over study. 24 patients with chronic an meeting the inclusion criteria will be randomized either to receive marinol® or placebo. after four weeks the two groups will undergo a wash-out period and after that will receive the opposite therapeutic regime for another four weeks.

Eligibility criteria:
inclusion criteria: * patients under treatment for an. * patients attending ambulatory treatment, which are not expected to be admitted at the hospital with an-related pathology or discharged during the study period. * patients admitted to department of endocrinology m or psychiatric department p which are not expected to be discharged during the study period. * age over 18. * duration of the disease over 5 years. exclusion criteria: * patients under compulsory treatment or suffering of mania, schizophrenia or primary depression. * patients with any medical or psychiatric event related or not related to the underlying eating disorder which requires prolonged admission to the hospital during the study. * patients with unstable heart disease (relevant changes in medication prior or during the study) and limitation of activity (not comfortable with more than moderate exertion / at rest). * patients not attending to the weekly controls. * if other severe adverse events (sae) / drug reactions (sadr) are suspected. * patients actually having or having a history of alcohol, cannabis, opioids or central stimulating drugs abuse. * patients with known allergy to dronabinol or sesame oil. * fertile, menstruating women not using safe contraception. * pregnancy.

Keywords: anorexia nervosa chronic dronabinol weight gain edi
safety and performance of the glyconics-sx system

Conditions: Diabetes Mellitus, Type 2

Summary: the main clinical study objective is to retrieve initial high quality spectra measurements indicative of the accuracy of the glyconics-sx system in distinguishing between individuals with or without t2dm based on known and/or assumed clinical status of the participants and as controlled by values of an internal biomarker indicative of glycaemia, hba1c, as measured with validated, comparator device.


Eligibility criteria:
inclusion criteria: * apparently healthy adults (≥18 years of age) with known or unknown t2dm status willing to participate in and provide a written consent for the study * willingness to undertake assisted assessment of glycaemia by both the nir spectra measurement, and hba1c by finger prick test * individuals with two visually assessed apparently healthy, undamaged, and intact fingernails, one in both right- and left-hand middle fingers exclusion criteria: * individuals with any known medical conditions impacting either of the assessment methodology for glycaemia, such as * anaemia (iron deficiency sickle cell anaemia or similar) * haemoglobinopathies or atypical haemoglobin subtypes not detectable by regular assays, * severe renal impairment (ckd stage iii-iv) or decompensated hepatic disease * severe vitamin d deficiency * known severe immunodeficiency such as hiv, malignancy or other chronic condition significantly impacting assessment of glycaemia * eating disorders (as per clinical assessment) * recent (within 28 days) blood donation * any structural, deviating and visually detectable deviations in the appearance of the nails potentially impacting the spectra measurement, including * nail dystrophy or deformity * severe nail infections (onychomycosis causing visual changes in the appearance of the nail) * rare hereditable conditions impacting the structure of keratin * mechanical damage or marks on the surface of the nail after removal of nail polish * use of acrylic or gel nail decoration and polish, which cannot be removed * any systemic or topical medication known to modify either the surface or structure of the nail or accuracy of hba1c value.